Attention Deficit and Hyperactivity DisorderStras-TDANCT03601858
Descriptive Epidemiology of a Specialized Consultation on ADHD in Adults at the Strasbourg University Hospital
An observational study of Attention Deficit and Hyperactivity Disorder, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
The main objective of this study is to carry out a descriptive study of the clinical and demographic characteristics of patients having consulted for a specialized opinion about ADHD in adults of the psychiatric service of the Strasbourg University Hospital. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Attention Deficit and Hyperactivity Disorder
- How many people
- 300 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jun 2018to Jun 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patient Having a specialized consultation about ADHD in adults in the psychiatric service of the Strasbourg University Hospital
Who may be able to join
- Age > 18
- Having a specialized consultation about ADHD in adults in the psychiatric service of the Strasbourg University Hospital
- Agree with the use of medical files from the consultation for medical research
Who cannot join
- Disgree with the use of medical files from the consultation for medical research
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Service de Psychiatrie II
Strasbourg, 67091
Sébastien Weibel, MD, 33 3 88 11 51 57, sebastien.weibel@chru-strasbourg.fr
About this study
Official title: Descriptive Epidemiology of a Specialized Consultation on Attention Deficit Hyperactivity Disorder in Adults at the Strasbourg University Hospital, and Evolution Analysis at One Year
The main objective of this study is to carry out a descriptive study of the clinical and demographic characteristics of patients having consulted for a specialized opinion about ADHD in adults of the psychiatric service of the Strasbourg University Hospital.
The characteristics of patients were collected during the first consultation, by the psychiatrist, and analyzed retrospectively.
Read more
The secondary objective is to evaluate the evolution at one year in terms of follow-up, maintenance under medical treatment and perceived effects of it.
The patients who had a prescription for pharmacological treatment of ADHD were contacted between 9 and 15 months after the first consultation and responded to a questionnaire assessing the evolution.
- Keywords
- Attention deficit, hyperactivity disorder, Adult, Epidemiology, Evolution, treatment
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity
What is being measured
The primary outcome is the main question the study is designed to answer.
Hyperactivity Disorder
Measuring from the medical files of patients and questionnaire
Measured: Between 9 and 15 months after the first consultation, contact of patients and collection of data for the evolution at one year analyze
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jul 2018
- Study start1 Jun 2018
- Primary completionJun 2019 (estimated)
- Study completionJun 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Attention Deficit and Hyperactivity DisorderStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03601858
- Sponsor's protocol ID
- 7083
- Acronym
- Stras-TDA
- Status last verified
- Jun 2018
- First submitted
- 3 Jul 2018
- Last updated
- 26 Jul 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jul 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Descriptive Epidemiology of a Specialized Consultation on Attention Deficit Hyperactivity Disorder in Adults at the Strasbourg University Hospital, and Evolution Analysis at One Year
- ClinicalTrials.gov ID
- NCT03601858
- Acronym / sponsor ID
- Stras-TDA / 7083
- Keywords
- Attention deficit, hyperactivity disorder, Adult, Epidemiology, Evolution, treatment
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 1 Jun 2018 (actual)
- Primary completion
- Jun 2019 (estimated)
- Study completion
- Jun 2019 (estimated)
- First posted
- 26 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this study is to carry out a descriptive study of the clinical and demographic characteristics of patients having consulted for a specialized opinion about ADHD in adults of the psychiatric service of the Strasbourg University Hospital.
The characteristics of patients were collected during the first consultation, by the psychiatrist, and analyzed retrospectively.
The secondary objective is to evaluate the evolution at one year in terms of follow-up, maintenance under medical treatment and perceived effects of it.
The patients who had a prescription for pharmacological treatment of ADHD were contacted between 9 and 15 months after the first consultation and responded to a questionnaire assessing the evolution.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patient Having a specialized consultation about ADHD in adults in the psychiatric service of the Strasbourg University Hospital
Key inclusion criteria (3 listed)
- Age > 18
- Having a specialized consultation about ADHD in adults in the psychiatric service of the Strasbourg University Hospital
- Agree with the use of medical files from the consultation for medical research
Key exclusion criteria (1 listed)
- Disgree with the use of medical files from the consultation for medical research
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Hyperactivity Disorder
Time frame: Between 9 and 15 months after the first consultation, contact of patients and collection of data for the evolution at one year analyze
Measuring from the medical files of patients and questionnaire
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jul 2018.
Related trials for Attention Deficit and Hyperactivity Disorder
Enrolling by invitationPhase 3
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
ADHD
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingObservational study
Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool
Disruptive Behavior Disorders, Conduct Disorder
Recruiting
Micronutrient Supplementation and Chronotherapy in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
ADHD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Attention Deficit and Hyperactivity Disorder, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Jul 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Sébastien Weibel, MD (33 3 88 11 51 57, sebastien.weibel@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hyperactivity Disorder (time frame: Between 9 and 15 months after the first consultation, contact of patients and collection of data for the evolution at one year analyze). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jul 2018.